Mark Goldsmith’s Form 4 filings over the past year paint a clear picture of a consistent seller in Revolution Medicines (RVMD), with no open-market purchases recorded. Across 39 transactions, all concentrated in the single biotech ticker, he disposed of shares worth approximately $36.6 million. The selling has been steady and recent: 18 open-market sales (code S) occurred in the last reporting window alone, including a blockbuster $18.0 million sale on April 15, 2026, and a cluster of 11 smaller sales on March 2, 2026, ranging from roughly $9,800 to $2.17 million. The most recent transaction, a $1.56 million sale on June 16, 2026, confirms the pattern remains active.
The filings also reveal the mechanics behind these disposals. Several sales were paired with option exercises (code M) — for instance, a $457,655 exercise on April 15, 2026, alongside the large sale, and a $122,700 exercise on March 2, 2026, preceding that day’s flurry of sales. These exercises are mechanical conversions of existing awards, not new capital commitments. Additionally, two zero-value grants (code A) on March 1, 2026, represent compensation, not purchases. The absence of any code P transactions — the only designation indicating a genuine open-market buy — underscores that Goldsmith’s activity is entirely one-directional: he is monetizing equity, not accumulating it.
The dollar figures are substantial relative to typical insider activity, with the April 2026 sale alone exceeding $18 million. While the pattern is unambiguous — a sustained, high-volume sell-down of RVMD shares with no corresponding buys — the filings themselves offer no insight into his reasoning. What the data shows is a senior figure (title listed as “See Remarks”) systematically reducing his position in Revolution Medicines over multiple quarters, with the most aggressive selling occurring in the spring of 2026.
AI-assisted summary